IGC Pharma Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for IGC Pharma, Inc. (IGC) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2019
Period EndingDec 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2019
Operating Activities
Net Income-7.12-13.00-11.51-15.02-8.81-4.10
Depreciation & Amortization0.620.640.660.650.480.06
Stock Based Compensation1.641.772.842.200.660.00
Change in Working Capital-0.071.890.792.56-3.290.38
Change in Accounts Receivable-0.01-0.030.010.05-0.040.00
Change in Inventory0.181.010.901.93-1.230.00
Change in Accounts Payable0.110.24-0.450.50-0.290.00
Change in Other Working Capital-0.350.670.34-0.43-1.730.00
Other Operating Activities0.145.320.004.770.83-0.28
Net Cash from Operating Activities-4.80-5.20-7.05-7.46-10.80-3.33
Investing Activities
Capital Expenditures-0.480.52-0.620.77-1.47-0.02
Purchases of Investments0.000.15-0.150.004.980.00
Sales/Maturities of Investments0.000.15-0.31-0.54-0.120.00
Other Investing Activities-0.330.000.000.005.08-0.20
Net Cash from Investing Activities-0.44-0.32-0.24-0.743.39-0.26
Financing Activities
Debt Repayment0.000.000.000.000.00-1.88
Common Stock Issued4.453.530.104.1514.1629.46
Net Cash from Financing Activities4.453.520.104.1414.6927.60
Summary
Effect of Forex Changes on Cash-0.01-0.01-0.08-0.030.02-0.06
Net Change in Cash-0.79-1.99-7.18-4.067.2924.01
Cash at Beginning of Period1.203.2010.4614.557.261.66
Cash at End of Period0.411.203.2010.4614.5525.61
Free Cash Flow-5.28-5.67-7.67-8.20-12.27-3.39
Supplemental Disclosures
Interest Paid0.000.000.000.000.000.01